StockNews.AI
MLTX
StockNews.AI
4 hrs

MLTX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

1. MoonLake's shares dropped over 80% after disappointing trial results. 2. One trial showed improvement, but failed to meet investor expectations. 3. Second trial did not meet its primary endpoint, causing skepticism. 4. Faruqi & Faruqi is investigating claims related to the stock drop. 5. The underwhelming data raises doubts about MoonLake's future potential.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The 80% drop in share price indicates severe negative market sentiment. Similar past events often led to long-term losses for companies.

How important is it?

The article discusses significant losses and ongoing investigations that can directly affect investor sentiment and stock performance.

Why Short Term?

Immediate market reactions generally reflect news; long-term impact depends on recovery efforts. Historical cases show prolonged effects if recovery is slow.

Related Companies

MLTX
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In MoonLake To Contact Him Directly To Discuss Their Options If you suffered significant losses in MoonLake stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. MoonLake Immunotherapeutics saw its shares plummet over 80% on Monday after disappointing results from two late-stage trials of its experimental drug, sonelokimab, for hidradenitis suppurativa. While one study showed a statistically significant improvement over placebo, the margin of benefit fell short of investor expectations. The second trial failed to meet its primary endpoint entirely, with the company citing an unexpectedly high placebo response. The underwhelming data has cast doubt on the drug's regulatory path and commercial potential, prompting skepticism from analysts and a sharp market sell-off. To learn more about the MoonLake investigation, go to www.faruqilaw.com/MLTX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d516bf4b-fab7-416f-a74a-ea4437d5b4b3

Related News